Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Tissue Regenix Group PLC - Leeds, England-based medical device company - Reports revenue of $24.5 million for 2022, up 24% from $19.7 million a year earlier. Particularly, BioRinse increased by 26% to $16.0 million from $12.7 million. Pretax loss narrows to $2.8 million from $5.1 million in 2021, as operating loss narrows to $2.0 million from $4.4 million. Declares no dividend for the year, unchanged from a year prior. Looking ahead, Tissue Regenix says it is well prepared for additional market fluctuations as markets continue to normalise post-pandemic.
Chair Jonathan Glenn says: ‘During what has been a year of immense progress with some notable milestones achieved, we have continued to demonstrate and realise operational and commercial growth.’
Current stock price: 0.61 pence each, up 0.5% on Tuesday around noon in London
12-month change: up 56%
Copyright 2023 Alliance News Ltd. All Rights Reserved.